SAVE THE DATE!
2021 HTRS Scientific Symposium
Registration is now open for the 2021 HTRS Scientific Symposium, scheduled for March 11-13, 2021 at the Loews Coronado Bay, San Diego, CA. Stay tuned for details regarding format, which will likely feature live and virtual presentations. The abstract submission process also is now open and will close October 29, 2020.
To register*, CLICK HERE
*Active HTRS members receive discounted registration as a benefit of membership. To join or renew your membership today, CLICK HERE. HTRS members, please check the Members-Only website page for your member code to use during registration.
HTRS will continue to be a comprehensive scientific meeting dedicated to continuing medical education and the advancement of clinical, translational, and basic science researched related to non-malignant blood disorders in both pediatric and adult medicine. Our target audience is:
- Clinicans and physician-scientists in pedatric and adult medicine, including related fields such as cardiology, pulmonology, and obstetrics/gynecology
- Medical students, trainees, and junior faculty
- Basic and translational scientists
- Nurses and nurse practitioners
- Physican assistants
- Pharmacists
- Any allied health professionals interested in hemostasis and/or thrombosis
- Industry colleagues
HTRS is closely monitoring the impact of COVID-19 on our plans for March 2021. We hope to meet in-person at the beautiful Loews Coronado Bay Resort. Yet even as we open registration for this live event, we are prepared to pivot to a hybrid meeting (some live content, some virtual) or even a completely virtual event if necessary for the health and well-being of our attendees.
Regardless of format, we look forward to exploring hot topics in hemostasis and thrombosis, including COVID-19 and its impact on our field. This Symposium will also feature new opportunities for early-stage physician-scientists and researchers, including additional oral abstract and poster sessions, interactive breakouts, and mentoring. Dynamic, lively scientific exchange in this collegial atmosphere can and will continue as we adapt to this “new normal.”
Highlights and Important Dates:
- REGISTRATION and ABSTRACT SUBMISSION are now open! Should circumstances require a pivot to a hybrid or vitual meeting format, HTRS will announce revised registration fees and refund the balance for anyone already registered as appropriate.
- TRAVEL AWARDS*: An increase number of travel awards are available in 2021 for trainees/early-career investigators including underrepresented minorities, allied health professionals, undergraduates, and those from North or Central America -- all of whom are first authors of thei highest-scoring abstracts submitted to the meeting
- CONTINUING EDUCATION CREDITS are offered through the joint providership of the Postgraduate Institute for Medicine and HTRS, including AMA PRA Category 1 Credits™ for physicians, ANCC Contact Hours for nurses, and ACPE Contact Hourse for pharmacists.
- SPONSORSHIP AND EXHIBITS - HTRS Corporate Colleagues and other industry supporters will offer exhibits, satellite symposia, and other special events to enhance the experience for full conference attendees.
*Please stay tuned: HTRS remains fully committed to distinguishing top abstracts with awards in 2021; however, adjustments may be made to the awards themselves, contingent on travel restrictions due to ongoing public health concerns.
2021 HTRS Research Colloquium
The HTRS 2021 Research Colloquium is rescheduled for March 8-9, 2021 as a live, online pre-conference to the HTRS 2021 Scientific Symposium on March 10-12, 2021.
For important info for new registrants, previous registrants, and award recipients, CLICK HERE. Questions? Email [email protected]..
It will be a dynamic meeting focused on professional development and networking in benign hematology for:
- Basic Scientists
- Translational Researchers
- Clinicians/Physician-Scientists
- Location: Pre-THSNA Summit 2020 at the Hyatt Regency Chicago
COLLOQUIUM AGENDA
REGISTRATION LINK: Registration is still open! Visit this link to submit a new application and upload supporting documents before Friday, December 18, 2020 by 11:59 PM ET.
For complete details, CLICK HERE
NHLBI News: Blueprint, Strategies and Tools for Future Factor VIII Inhibitor-Related Research
Factor VIII Inhibitor State of the Science Workshop Proceedings were published in the July 2019 edition of Hemophilia - Volume 24, Issue 4.
READ MORE
Abstracts from 2019 Symposium published in Haemophilia
The Abstracts from the HTRS/NASTH 2019 Scientific Symposium were published in Haemophilia, the official journal of HTRS.
READ MORE
Podcast: NHLBI Resources and Grants for Hematologists with Drs. DiMichele and Hoots
How to maximize research training and funding opportunities for non-malignant hematology and blood science investigators is the subject of this free podcast, in which Dr. Donna DiMichele and Dr. Keith Hoots of the National Heart, Lung, and Blood Institute (NHLBI) talk about NHLBI and National Institutes of Health resources and grants available to hematologists.
READ MORE
Join a Registry
The Children’s Hospital-Acquired Thrombosis (CHAT) Study
Factor X: From Thrombokinase to Oral Anticoagulants and Beyond ~ Friday, November 6, 2020
Live Zoom Webinar: 8:00 AM - 4:30 PM ET
Focused on Coagulation Factor X, this one-day Yale symposium for multiple specialties includes internationally recognized experts who made significant contributions to the current understanding of structure, function and medical significance of Factor X.
Objectives:
- Review the central role of Factor Xa in the coagulation process
- Appreciate the complexity of Factor Xa activities and co-factor interaction
- Discuss how Factor Xa became the focus of anticoagulant therapy
- Explore the discovery of non-enzymatic properties of Factor X
Registration:
- Registration (no CME credit) - complimentary, online registration required
- General Registration (CME credit included) - $25
- Residents/Fellows/Students - complimentary, online registration required
For full details, CLICK HERE
National Institutes of Health Center for Scientific Review
The Center for Scientific Review (CSR) at the National Institutes of Health (NIH) offers two programs that could be valuable for HTRS members:
EARLY CAREER REVIEWER PROGRAM:
Early career scientists who would like review experience can apply to participate in the NIH Early Career Reviewer (ECR) Program. The goals of the ECR Program are to help early career scientists become more competitive as grant applicants through first-hand experience with peer review and to enrich and diversify CSR's pool of trained reviewers.
For more info or to apply to the ECR Program, please CLICK HERE
SCIENTIFIC SOCIETY- REVIEWER RECOMMENDATIONS PORTAL:
HTRS members are invited to recommend scientists to serve as grant reviewers through the NIH Review Recommendation portal. Reviewers should be scientists who are generally willing to serve as reviewers and are seen as experts, with integrity, in their field. They should have an active research program, extramural funding, and not currently be a standing member of an NIH study section or advisory council. The NIH is encouraging HTRS to recommend productive scientists from diverse backgrounds and career stages – e.g. assistant, associate, and full professors.
If you would like HTRS to nominate you or a colleague as an NIH reviewer, please email [email protected] for more info.
FWGBD: Free Webinar October 9th to focus on Long-Acting Reversible Contraception (LARC) use
Join FWGBD for a free webinar on Friday, October 9, 2020 from 1:00-2:00 PM ET entitled, "Addressing the Use of Long-Acting Reversible Contraception (LARC), with Special Considerations for Use with Young Women and Women with Heavy Menstrual Bleeding."
Led by faculty Dr. Oluyemisi Adeyemi-Fowode, HTRS Member Dr. Allison Paroski Wheeler, and moderator Dr. Claudia Borzutzky, this state-of-the-science Webinar will offer current best practices on the use and management of long-acting reversible contraception (LARC) in women of reproductive age, focusing on women who are at risk of experiencing heavy menstrual bleeding (HMB). Free CMEs will be offered.
This Webinar is supported in part through an educational grant from Bayer Pharmaceuticals.
To register, please CLICK HERE
2020 HTRS/ATHN Dataset Research Engagement and ATHN Mentorship ("DREAM") Award: Deadline has passed
Together, we're helping turn dreams into reality. The DREAM Award is offered through the collaboration of HTRS and ATHN and supported by an independent medical educational grant from Takeda. Key details:
- Applicants residing in the U.S. and working at U.S.-based, ATHN-affiliated HTCs were eligible to apply for a 2020 DREAM Award.
- The award offers funding of $50,000 USD per recipient for projects lasting up to one year and $100,000 USD per recipient for projects lasting up to two years.
READ MORE
2020 HTRS Student Research Awards: Deadline has passed
The deadline has passed for the Hemostasis and Thrombosis Research Society (HTRS) Student Research Award, an 8- to 10-week program for medical, PhD, MD/PhD, or PharmD students working on targeted research projects in hemostasis and thrombosis. Proposed projects may be lab-based, clinical or epidemiologic in design. The program includes a $5,000 award stipend plus a $2,000 travel allowance, collaboration with a research mentor, and a presentation at a 2021 professional meeting. Watch for more details late 2020 for next year's program.
READ MORE
Dr. Anthony Fauci praises HTRS Member Lisa Baumann Kreuziger for her work on national COVID-19 panel
Dr. Lisa Baumann Kreuziger, MD, MS, Medical Director at the Versiti Blood Center of Wisconsin, was praised in a personal letter of gratitude from White House advisor and director of the National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci.
A hematology expert, Dr. Baumann Kreuziger is serving on a national COVID-19 panel that recommends the best treatment options for people with the virus. The guidelines have been developed to inform clinicians how to care for patients with COVID-19, she says.
"You responded in an exceptional way and worked tirelessly to develop an outstanding initial set of guidelines in two weeks," wrote Dr. Fauci. "In the first week after their release on April 21, there were more than 1 million page views, highlighting the importance of your work. Thank you again for your contributions to this panel, for your outstanding work in caring for patients and for all the additional ways you are helping to respond to this pandemic during this most extraordinary time."
Says Dr. Baumann Kreuziger, "I was honored and humbled to be part of a group of experts to establish treatment recommendations. The guidelines have provided a review of evidence on which doctors can treat patients and develop research."